Evaluation of Articaine 4% Versus Mepivacaine 2% for Surgery of Molars Thirds: Clinical Trial.
Launched by UNIVERSIDADE ESTADUAL PAULISTA JÚLIO DE MESQUITA FILHO · Dec 22, 2017
Trial Information
Current as of August 14, 2025
Completed
Keywords
ClinConnect Summary
This study will compare the use of Articaine at 4% to that of Mepivacaine at 2% for lower third molar surgeries semi-included and / or included. I will select 16 patients who require surgical treatment for extraction of third molars, aged between 16 and 40 years at the São Paulo State University. These will participate simultaneously in the two groups: Group 1 mepivacaine (MEP) and Group 2 articaine (ART), and the division will be performed by randomization, so that each patient will have each side (right or left) allocated in different groups. The primary evaluation variable will be to com...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • American Society of Anesthesiologists Classification -(ASA I) patients;
- • Patients with need for extraction of lower third molars included and / or semi-included;
- • Teeth in opposing hemiarch with the same classifications as Pell and Gregory and Winter;
- • Age between 16 and 40 years;
- • Patients who agree to voluntarily participate in the survey.
- Exclusion Criteria:
- • History of allergic reactions (hypersensitivity) to anesthetics;
- • Patients presenting with local or systemic alterations that contraindicate the procedure;
- • Current use of drugs that may interfere with the action of anesthetics;
- • Need for sedatives or anxiolytic drugs during extraction;
- • Pregnancy or breastfeeding;
- • Third erupted lower third molars.
About Universidade Estadual Paulista Júlio De Mesquita Filho
Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP) is a prominent public research university in Brazil, recognized for its commitment to advancing scientific knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, UNESP leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous clinical research aimed at improving patient outcomes and advancing medical practices. The university fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring adherence to ethical standards and regulatory compliance throughout the research process. UNESP's dedication to excellence in clinical trials contributes significantly to the global body of medical knowledge and public health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
São José Dos Campos, Sp, Brazil
Patients applied
Trial Officials
Michelle B Moraes, PHD
Principal Investigator
Universidade Estadual Paulista Júlio de Mesquita Filho-Unesp
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials